Health Care Innovation
Blog
Here They Go Again: The Democratic Obsession with Drug Price Controls Will Harm Patients and Diminish Innovation
The U.S. House of Representatives is once again considering “The Lower Drug Costs Now Act”. It was a bad idea in the last Congress, and it is still bad policy today. If it becomes law, this Act (H.R. 3) empowers the federal government to negotiate prices on select drugs for ...
Commentary
Drug Importation Programs Come At Too High a Cost
Lawmakers in Colorado are trying to open their state’s borders to prescription drugs from abroad. In 2019, they green-lit imports from Canada. They’re still working on a plan to implement that policy that can garner federal approval. Then last week, legislators approved a bill that would allow Coloradans to import prescription drugs ...
Commentary
Violating intellectual property rights jeopardizes quality health care
Policymakers across the globe are attempting to vilify the same private companies that have been invaluable partners in the fight against the COVID-19 pandemic. If these efforts are successful, it will be patients who are harmed the most. Globally, the World Trade Organization (WTO) wants to waive the patent rights for the ...
Drug Pricing
ISSUE BRIEF: ICER Analyses Are Flawed, Undervalue Life-Saving Medicines, and Are Biased Toward Price Controls
A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no ...
Commentary
Frivolous Patent Litigation Threatens The Technology Revolution
Patent trolls have been a plague on innovators for too long. Patent trolls are entities that obtain patents (sometimes obscure patents) for the sole purpose of threatening or filing lawsuits in court and then using the prospect of costly litigation to extort unwarranted payouts from an innovative company. The risks ...
Commentary
President Biden’s Bipartisan Opportunity to Reduce Patients’ Drug Costs
BY ROBERT POPOVIAN & WAYNE WINEGARDEN President Joe Biden should take advantage of a bipartisan opportunity to meaningfully reduce patients’ out-of-pocket spending on biopharmaceuticals. Seizing this opportunity requires the president to recognize that the drug cost problem exists because the current system inappropriately shifts too much of its expenditures to patients. Consider that ...
Health Care
Healthcare Policy During COVID-19 – Sacramento Policy Conference
This podcast is a recording of the health care panel discussion at PRI’s virtual Sacramento Policy Conference. Our All-Star panelists include Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy; Wayne Winegarden, PRI senior fellow in business and economics and director of PRI’s Center for ...
Commentary
Biden’s health care plans – this is what Americans can expect from Democrats
Last week, President Joe Biden signed executive orders that will re-open ObamaCare’s insurance exchanges from Feb. 15 through May 15 and direct federal agencies to re-examine some of the health care rules enacted by the Trump administration. There’s a limit to what Biden can accomplish by executive action. But with narrow control of Congress, there’s still plenty ...
Blog
It’s the Payment System
Effectively addressing the drug affordability problem requires an understanding of its causes. Toward this end, the rhetoric of Matt Eyles, the president and chief executive of America’s Health Insurance Plans (AHIP), is unhelpful. According to Eyles, “Americans are being hurt by out-of-control drug prices, which are set and fully controlled ...
Commentary
Biden officials threaten to jumpstart single-payer health care systems
Move over, Bidencare. Single-payer health care could be coming to the United States. President-elect Joe Biden’s nominee to lead the Department of Health and Human Services, California Attorney General Xavier Becerra, is a longtime supporter of Medicare for All. If confirmed, he’ll have the power to approve waivers that would allow states ...
Here They Go Again: The Democratic Obsession with Drug Price Controls Will Harm Patients and Diminish Innovation
The U.S. House of Representatives is once again considering “The Lower Drug Costs Now Act”. It was a bad idea in the last Congress, and it is still bad policy today. If it becomes law, this Act (H.R. 3) empowers the federal government to negotiate prices on select drugs for ...
Drug Importation Programs Come At Too High a Cost
Lawmakers in Colorado are trying to open their state’s borders to prescription drugs from abroad. In 2019, they green-lit imports from Canada. They’re still working on a plan to implement that policy that can garner federal approval. Then last week, legislators approved a bill that would allow Coloradans to import prescription drugs ...
Violating intellectual property rights jeopardizes quality health care
Policymakers across the globe are attempting to vilify the same private companies that have been invaluable partners in the fight against the COVID-19 pandemic. If these efforts are successful, it will be patients who are harmed the most. Globally, the World Trade Organization (WTO) wants to waive the patent rights for the ...
ISSUE BRIEF: ICER Analyses Are Flawed, Undervalue Life-Saving Medicines, and Are Biased Toward Price Controls
A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no ...
Frivolous Patent Litigation Threatens The Technology Revolution
Patent trolls have been a plague on innovators for too long. Patent trolls are entities that obtain patents (sometimes obscure patents) for the sole purpose of threatening or filing lawsuits in court and then using the prospect of costly litigation to extort unwarranted payouts from an innovative company. The risks ...
President Biden’s Bipartisan Opportunity to Reduce Patients’ Drug Costs
BY ROBERT POPOVIAN & WAYNE WINEGARDEN President Joe Biden should take advantage of a bipartisan opportunity to meaningfully reduce patients’ out-of-pocket spending on biopharmaceuticals. Seizing this opportunity requires the president to recognize that the drug cost problem exists because the current system inappropriately shifts too much of its expenditures to patients. Consider that ...
Healthcare Policy During COVID-19 – Sacramento Policy Conference
This podcast is a recording of the health care panel discussion at PRI’s virtual Sacramento Policy Conference. Our All-Star panelists include Sally Pipes, PRI President, CEO, and Thomas W. Smith Fellow in Health Care Policy; Wayne Winegarden, PRI senior fellow in business and economics and director of PRI’s Center for ...
Biden’s health care plans – this is what Americans can expect from Democrats
Last week, President Joe Biden signed executive orders that will re-open ObamaCare’s insurance exchanges from Feb. 15 through May 15 and direct federal agencies to re-examine some of the health care rules enacted by the Trump administration. There’s a limit to what Biden can accomplish by executive action. But with narrow control of Congress, there’s still plenty ...
It’s the Payment System
Effectively addressing the drug affordability problem requires an understanding of its causes. Toward this end, the rhetoric of Matt Eyles, the president and chief executive of America’s Health Insurance Plans (AHIP), is unhelpful. According to Eyles, “Americans are being hurt by out-of-control drug prices, which are set and fully controlled ...
Biden officials threaten to jumpstart single-payer health care systems
Move over, Bidencare. Single-payer health care could be coming to the United States. President-elect Joe Biden’s nominee to lead the Department of Health and Human Services, California Attorney General Xavier Becerra, is a longtime supporter of Medicare for All. If confirmed, he’ll have the power to approve waivers that would allow states ...
